Kovitz Investment Group Partners LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Kovitz Investment Group Partners LLC bought a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $224,000.

Separately, Caas Capital Management LP purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter valued at $672,000.

TSHA stock opened at $21.17 on Friday. Taysha Gene Therapies, Inc. has a 52 week low of $18.16 and a 52 week high of $27.53.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, November 12th. The company reported ($1.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($1.27). Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -1.35 earnings per share for the current year.

Several analysts have recently weighed in on TSHA shares. Jefferies Financial Group started coverage on shares of Taysha Gene Therapies in a research report on Monday, October 19th. They set a “buy” rating and a $34.00 price objective on the stock. Chardan Capital started coverage on shares of Taysha Gene Therapies in a research report on Monday, October 19th. They set a “buy” rating and a $45.00 price objective on the stock. Morgan Stanley started coverage on shares of Taysha Gene Therapies in a research report on Monday, October 19th. They set an “overweight” rating and a $29.00 price objective on the stock. Finally, The Goldman Sachs Group started coverage on shares of Taysha Gene Therapies in a research report on Monday, October 19th. They set a “buy” rating and a $31.00 price objective on the stock.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency.

Featured Article: Using other technical indicators with support levels

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA).

Institutional Ownership by Quarter for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.